Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Celecoxib + Cyclophosphamide + Etoposide + Sirolimus|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Celecoxib||Celebra||Celebra (celecoxib) is a COX-2 inhibitor FDA approved as an anti-inflammatory agent and for colorectal polyp reduction (FDA.gov) and also promotes apoptosis of tumor cells (PMID: 17909047).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Etoposide||Vepesid||EPEG|Eposin|VP-16|VP-16-213||TOPO2 inhibitor 4||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Sirolimus||Rapamune||Rapamycin||mTORC1 Inhibitor 8||Rapamune (sirolimus) binds to the FKBP-12 to generate an immunosuppressive complex that binds and allosterically inhibits mTOR (PMID: 25261369). Rapamune (sirolimus) is FDA approved for the prevention of renal transplant rejection and for patients with lymphangioleiomyomatosis (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02574728||Phase II||Celecoxib + Cyclophosphamide + Etoposide + Sirolimus||Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors||Recruiting|
|NCT04469530||Phase II||Celecoxib + Cyclophosphamide + Etoposide + Sirolimus||Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903)||Not yet recruiting|